Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children

被引:32
|
作者
Giachetto, Gustavo A.
Telechea, Hector M. [1 ]
Speranza, Noelia [1 ]
Oyarzun, Mireille [1 ]
Nanni, Luciana [2 ]
Menchaca, Amanda
机构
[1] Univ Republica, Coll Med, Dept Pharmacol, Pediat Intens Care Dept, Montevideo, Uruguay
[2] Ctr Hosp Pereira Rossell, Dept Pharm, Montevideo, Uruguay
关键词
critical ill children; pharmacokinetics/pharmacodynamics; vancomycin; RESISTANT STAPHYLOCOCCUS-AUREUS; REDUCED SUSCEPTIBILITY; INFECTIONS;
D O I
10.1097/PCC.0b013e3181fe4047
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Critically ill children may present changes in pharmacokinetic parameters and may not reach effective concentrations of vancomycin with current dosages. The objective of this study is to calculate vancomycin pharmacokinetic parameters in critically ill children and to estimate area under the curve at 24 hrs/minimal inhibitory concentration reached for Staphylococcus aureus. Design, Setting, and Patients: Children treated with vancomycin, hospitalized in the Intensive Care Unit of the Pediatric Hospital-Centro Hospitalario Pereira Rossell, were included. Samples to determine vancomycin serum concentration were obtained on first and third days of treatment, 1 hr after the end of the third daily dose administration (maximum drug concentration) and 15 mins before the fourth (minimum drug concentration). Half-life elimination, volume of distribution, clearance, and area under the curve at 24 hrs were estimated. Vancomycin concentration values of 20-40 mu g/mL (maximum drug concentration) and 5-10 mu g/mL (minimum drug concentration) were considered therapeutic. Measurements and Main Results: Twenty-two children were included. On day 1, seven of 18 children for maximum drug concentration and 16 of 22 for minimum drug concentration reached concentrations in therapeutic range; on day 3, seven of 16 children for maximum drug concentration and 11 of 17 for minimum drug concentration did. Mean values of maximum drug concentration and minimum drug concentration were higher in children with negative water balance. Mean value of half-life elimination increased from day 1 to day 3. Considering a value of minimal inhibitory concentration for S. aureus of 1 mu g/mL, nine of 18 children reached a relationship area under the curve at 24 hrs/minimal inhibitory concentration >400 on day 1 and seven of 15 on day 3. Considering a minimal inhibitory concentration of 2 mu g/mL, one child reached it on day 1 and one on day 3. Conclusions: Critically ill children show changes in pharmacokinetic parameters. Serum concentration monitorization is necessary for dosage individualization. Most children do not reach an area under the curve at 24 hrs/minimal inhibitory concentration >400 with current dosage. (Pediatr Crit Care Med 2011; 12:e250-e254)
引用
收藏
页码:E250 / E254
页数:5
相关论文
共 50 条
  • [31] Evaluation of a pharmacokinetic-pharmacodynamic approach using software to optimize the carbapenem antibiotic regimen
    Ishihara, Noriyuki
    Nishimura, Nobuhiro
    Tamaki, Hiroki
    Karino, Funni
    Miura, Kiyotaka
    Isobe, Takeshi
    Ikawa, Kazuro
    Morikawa, Norifumi
    Naora, Kohji
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (06) : 422 - 429
  • [32] Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future
    Sturkenboom, Marieke G. G.
    Akkerman, Onno W.
    Bolhuis, Mathieu S.
    de Lange, Wiel C. M.
    van der Werf, Tjip S.
    Alffenaar, Jan-Willem C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 2474 - 2474
  • [33] Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients
    Stein, Gary E.
    Smith, Curtis L.
    Scharmen, Amy
    Kidd, James M.
    Cooper, Christopher
    Kuti, Joseph
    Mitra, Subhashis
    Nicolau, David P.
    Havlichek, Daniel H.
    SURGICAL INFECTIONS, 2019, 20 (01) : 55 - 61
  • [34] PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF LEVETIRACETAM IN CRITICALLY ILL PATIENTS WITH SAH
    Van Matre, Edward
    Mueller, Scott
    Neumann, Robert
    Cava, Luis
    MacLaren, Robert
    Kiser, Tyree
    CRITICAL CARE MEDICINE, 2020, 48
  • [35] Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches
    Conil, Jean-Marie
    Georges, Bernard
    de Lussy, Anne
    Khachman, Dalia
    Seguin, Thierry
    Ruiz, Stephanie
    Cougot, Pierre
    Fourcade, Olivier
    Houin, Georges
    Saivin, Sylvie
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (06) : 505 - 510
  • [36] Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill
    Tsai, Danny
    Lipman, Jeffrey
    Roberts, Jason A.
    CURRENT OPINION IN CRITICAL CARE, 2015, 21 (05) : 412 - 420
  • [37] A PHARMACOKINETIC EVALUATION OF VANCOMYCIN AND CEFEPIME IN CRITICALLY ILL NEUROSURGICAL PATIENTS
    Anliker, Lynn
    Foster, Charles
    Kiser, Tyree
    Mueller, Scott
    Sherman, Deb
    MacLaren, Robert
    Neumann, Robert
    Fish, Douglas
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U255 - U255
  • [38] Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients
    Alvarez, Osvaldo
    Cristian Plaza-Plaza, Jose
    Ramirez, Manuel
    Peralta, Alexis
    Amador, Cristian A.
    Amador, Roberto
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [39] Improving Vancomycin Stewardship in Critically Ill Children
    Chiotos, Kathleen
    Fitzgerald, Julie C.
    Hayes, Molly
    Dashefsky, Hannah
    Metjian, Talene A.
    Woods-Hill, Charlotte
    Biedron, Lauren
    Stinson, Hannah
    Ku, Brandon C.
    Tighe, Sheila Robbins
    Weiss, Scott L.
    Balamuth, Fran
    Schriver, Emily
    Gerber, Jeffrey S.
    PEDIATRICS, 2022, 149 (04)
  • [40] Clinical Pharmacokinetics of Vancomycin in Critically Ill Children
    Sridharan, Kannan
    Al Daylami, Amal
    Ajjawi, Reema
    Al-Ajooz, Husain
    Veeramuthu, Sindhan
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (06) : 807 - 816